文献速递胸部肿瘤放疗

新辅助低剂量放疗联合度伐利尤单抗和化疗治疗潜在可切除III期非小细胞肺癌:一项Ib期剂量递增研究

Neoadjuvant low-dose radiotherapy plus durvalumab and chemotherapy for potentially resectable stage III NSCLC: A phase Ib dose-escalation study.
PubMed 文献 · Radiother Oncol · 2024-04-26

该Ib期研究评估新辅助低剂量放疗联合度伐利尤单抗和标准化疗在潜在可切除III期非小细胞肺癌中的安全性/耐受性和初步抗肿瘤活性,采用3+3设计剂量递增(10 Gy/5次、20 Gy/10次、30 Gy/15次),共入组9例患者,未记录剂量限制性毒性,3例(33.3%)发生3-4级治疗相关不良事件,7例(77.8%)成功转化为可切除并实现R0切除,结论认为该联合方案耐受良好,初步疗效支持其潜力,最佳放疗剂量确定为30 Gy/15次,需进一步临床研究。

要点

  • 9例潜在可切除III期NSCLC患者接受新辅助低剂量放疗联合度伐利尤单抗和化疗,未记录剂量限制性毒性。
  • 3例(33.3%)发生3-4级治疗相关不良事件,无治疗相关手术延迟或死亡。
  • 7例(77.8%)成功转化为可切除并实现R0切除,最佳放疗剂量确定为30 Gy/15次。

核心结论

  • 新辅助低剂量放疗联合度伐利尤单抗和化疗在潜在可切除III期NSCLC中耐受良好,初步疗效支持该联合方案的潜力,最佳放疗剂量确定为30 Gy/15次,需进一步临床研究。

研究设计与样本

  • Ib期剂量递增研究,采用3+3设计,放疗剂量递增为10 Gy/5次(队列1)、20 Gy/10次(队列2)、30 Gy/15次(队列3),同步度伐利尤单抗联合标准化疗2周期,共入组9例潜在可切除III期NSCLC患者。

主要发现

  • 9例患者完成计划新辅助治疗,未记录剂量限制性毒性,3例(33.3%)发生3-4级治疗相关不良事件。
  • 7例(77.8%)成功转化为可切除并实现R0切除,无治疗相关手术延迟或死亡。
  • 主要病理缓解率和病理完全缓解率:队列1均为33.3%(1/3),队列2分别为66.7%(2/3)和0.0%,队列3分别为100.0%(3/3)和66.7%(2/3)。
  • 数据截止时,12个月无事件生存率在三个队列分别为33.3%、66.7%和100%。
  • 生物标志物分析显示,病理学或影像学缓解者的肿瘤突变负荷值均高于其他患者(所有p>0.05)。

局限性

  • 原文结论指出需进一步临床研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: This phase Ib study was designed to assess the safety/tolerability and preliminary antitumor activity of neoadjuvant low-dose radiotherapy (LDRT) plus durvalumab and chemotherapy for potentially resectable stage III non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: Eligible patients received dose-escalated radiotherapy (10 Gy in 5 fractions [cohort 1], 20 Gy in 10 fractions [cohort 2], and 30 Gy in 15 fractions [cohort 3]) according to a 3 + 3 design, with concurrent durvalumab plus standard chemotherapy for two cycles. Primary objective was safety/tolerability. Secondary objectives included major pathological response (MPR), pathological complete response (pCR), event-free survival (EFS), and exploratory biomarker analysis. RESULTS: Nine patients were enrolled and completed the planned neoadjuvant therapy. No dose-limiting toxicity was recorded. Grade 3-4 treatment-related adverse events were observed in three (33.3 %) patients. Seven (77.8 %) patients successfully converted to resectable cases with R0 resection. No treatment-related surgical delay or death was reported. The MPR and pCR rates were both 33.3 % % (1/3) for cohort 1, 66.7 % (2/3) and 0.0 % for cohort 2, and 100.0 % (3/3), and 66.7 % (2/3) for cohort 3. At data cutoff, the 12 month-EFS rates were 33.3 %, 66.7 %, and 100 % for three cohorts, respectively. By biomarker analysis, TMB values were higher in either pathologically or radiologically responders than in others (all p > 0.05). CONCLUSION: Neoadjuvant LDRT plus durvalumab and chemotherapy was well-tolerated in potentially resectable stage III NSCLC. The preliminary efficacy supports this combined regimen's potential, the optimal radiotherapy dosage was determined to be 30 Gy in 15 fractions, warranting further clinical investigation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Li J, Lu S, Tian Y, et al. Neoadjuvant low-dose radiotherapy plus durvalumab and chemotherapy for potentially resectable stage III NSCLC: A phase Ib dose-escalation study. Radiother Oncol. 2024. PMID: 38679201. doi:10.1016/j.radonc.2024.110316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。